The study detailed the results of a trial involving 2,246 unvaccinated, nonhospitalized patients at high risk of their case progressing to severe COVID-19. The researchers gave 1,120 participants Paxlovid and the other 1,126 participants received a placebo.
Participants in the Paxlovid group were 88.9 percent less likely to die or be hospitalized compared with those in the placebo group. The pill presented no evident safety concerns, according to the study.
Read the full study here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.